# SEM — Select Medical Holdings Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SEM  
**Sources:** 14  
**Published:** 2026-10-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-sem-select-medical-holdings-corp-catalysts-narrative-ris-10136

---

## Status note (point-in-time: 2026-10-30)

As of October 30, 2026, Select Medical Holdings Corp (NYSE: SEM) is **no longer a publicly traded stock**. A consortium led by co-founder/Executive Chairman Robert A. Ortenzio, Senior EVP Martin F. Jackson, and private-equity sponsor Welsh, Carson, Anderson & Stowe (WCAS) completed its acquisition on June 30, 2026, and the stock was delisted and marked inactive at a last trade of $16.51 on June 30, 2026 ([[10]](https://stockanalysis.com/stocks/sem/forecast/), [[13]](https://stockanalysis.com/stocks/sem/), [[14]](https://stockanalysis.com/stocks/sem/revenue/)). Public shareholders were to receive $16.50 per share in cash ([[1]](https://flash.stocksentinel.ai/research/SEM)). Below is a reconstruction of the recent catalysts, narratives, and risks, with the take-private transaction as the dominant theme.

## Recent catalysts (last ~1–3 months; July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-sem-select-medical-holdings-corp-catalysts-narrative-ris-10136 (free to sign up)._